Pure Biologics Spólka Akcyjna (PUR.WA)

PLN 9.19

(-3.26%)

EBITDA Summary of Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna's latest annual EBITDA in 2023 was -26.07 Million PLN , down -9.74% from previous year.
Pure Biologics Spólka Akcyjna's latest quarterly EBITDA in 2024 Q2 was 889 Thousand PLN , up 120.36% from previous quarter.
Pure Biologics Spólka Akcyjna reported an annual EBITDA of -22.77 Million PLN in 2022, down -191.92% from previous year.
Pure Biologics Spólka Akcyjna reported an annual EBITDA of -7.53 Million PLN in 2021, up 9.14% from previous year.
Pure Biologics Spólka Akcyjna reported a quarterly EBITDA of -4.33 Million PLN for 2024 Q1, up 50.99% from previous quarter.
Pure Biologics Spólka Akcyjna reported a quarterly EBITDA of -4.85 Million PLN for 2023 Q3, up 36.19% from previous quarter.

Annual EBITDA Chart of Pure Biologics Spólka Akcyjna (2023 - 2016)

Historical Annual EBITDA of Pure Biologics Spólka Akcyjna (2023 - 2016)

Year	EBITDA	EBITDA Growth
2023	-26.07 Million PLN	-9.74%
2022	-22.77 Million PLN	-191.92%
2021	-7.53 Million PLN	9.14%
2020	-8.29 Million PLN	-126.81%
2019	-1.64 Million PLN	-687.53%
2018	-464.5 Thousand PLN	-87.62%
2017	-247.57 Thousand PLN	35.56%
2016	-384.21 Thousand PLN	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	889 Thousand PLN	120.36%
2024 Q1	-4.33 Million PLN	50.99%
2023 Q3	-4.85 Million PLN	36.19%
2023 Q4	-8.91 Million PLN	-83.41%
2023 Q1	-4.69 Million PLN	35.89%
2023 Q2	-7.61 Million PLN	-62.19%
2023 FY	- PLN	-9.74%
2022 Q2	-5.81 Million PLN	-20.78%
2022 Q4	-7.32 Million PLN	-28.52%
2022 FY	- PLN	-191.92%
2022 Q1	-4.81 Million PLN	-37146.15%
2022 Q3	-5.69 Million PLN	2.06%
2021 Q1	-2.84 Million PLN	15.8%
2021 FY	- PLN	9.14%
2021 Q3	-3.43 Million PLN	-40.1%
2021 Q4	13 Thousand PLN	100.38%
2021 Q2	-2.45 Million PLN	13.74%
2020 Q4	-3.37 Million PLN	-148.82%
2020 FY	- PLN	-126.81%
2020 Q2	-2.28 Million PLN	-67.47%
2020 Q3	-1.35 Million PLN	40.44%
2020 Q1	-1.36 Million PLN	21.9%
2019 Q2	-1.04 Million PLN	-374.61%
2019 Q1	-221.03 Thousand PLN	-78.45%
2019 FY	- PLN	-687.53%
2019 Q4	-1.74 Million PLN	-170.24%
2019 Q3	-645.02 Thousand PLN	38.51%
2018 Q3	-231.18 Thousand PLN	-177.63%
2018 FY	- PLN	-87.62%
2018 Q1	-26.19 Thousand PLN	26.48%
2018 Q2	-83.27 Thousand PLN	-217.83%
2018 Q4	-123.86 Thousand PLN	46.42%
2017 Q3	247.91 Thousand PLN	0.0%
2017 FY	- PLN	35.56%
2017 Q4	-35.63 Thousand PLN	-114.37%
2016 FY	- PLN	0.0%

Peer EBITDA Comparison of Pure Biologics Spólka Akcyjna

Name	EBITDA	EBITDA Difference
Bioceltix S.A.	-13.22 Million PLN	-97.189%
BIOTON S.A.	43.89 Million PLN	159.405%
Captor Therapeutics Spolka Akcyjna	-64.76 Million PLN	59.735%
Mabion S.A.	58.31 Million PLN	144.719%
Molecure S.A.	-25.5 Million PLN	-2.239%
NanoGroup S.A.	-7.87 Million PLN	-231.336%
Pharmena S.A.	33.78 Million PLN	177.197%
Poltreg S.A.	-11.65 Million PLN	-123.664%
Ryvu Therapeutics S.A.	-81.04 Million PLN	67.824%
Synthaverse S.A.	15.34 Million PLN	269.927%
Urteste S.A.	-5.73 Million PLN	-355.017%